Business Segments (Tables)

6 Months Ended

Jun. 30, 2012

Segment Reporting [Abstract]

Summary of segmental information

	Three Months Ended June 30,
	2012			2011
Revenues, Principally from Grants
Vaccines/BioDefense	$	710,237		$	335,029
BioTherapeutics		52,614			70,791
Total	$	762,851		$	405,820
Loss from Operations
Vaccines/BioDefense	$	(2,144	)	$	(67,425	)
BioTherapeutics		(481,817	)		(1,663,402	)
Corporate		(497,716	)		(201,963	)
Total	$	(981,677	)	$	(1,932,790	)
Amortization and Depreciation Expense
Vaccines/BioDefense	$	24,954		$	10,183
BioTherapeutics		25,892			43,290
Corporate		562			542
Total	$	51,408		$	54,015
Interest Income, Net
Corporate	$	1,799		$	1,473
Stock-Based Compensation
Vaccines/BioDefense	$	2,130		$	18,416
BioTherapeutics		56,194			188,255
Corporate		59,064			25,198
Total	$	117,388		$	231,869

	Six Months Ended June 30,
	2012			2011
Revenues, Principally from Grants
Vaccines/BioDefense	$	1,307,842		$	871,615
BioTherapeutics		102,427			342,210
Total	$	1,410,269		$	1,213,825
Income (Loss) from Operations
Vaccines/BioDefense	$	(130,509	)	$	52
BioTherapeutics		(1,207,859	)		(3,044,729	)
Corporate		(1,084,299	)		(610,959	)
Total	$	(2,422,667	)	$	(3,655,636	)
Amortization and Depreciation Expense
Vaccines/BioDefense	$	52,951		$	19,872
BioTherapeutics		54,733			84,491
Corporate		1,069			1,080
Total	$	108,753		$	105,443
Interest Income, Net
Corporate	$	4,034		$	3,908
Stock-Based Compensation
Vaccines/BioDefense	$	4,260		$	36,832
BioTherapeutics		112,614			286,508
Corporate		118,128			65,296
Total	$	235,002		$	388,636

	As of June 30,  2012		As of December 31, 2011
Identifiable Assets
Vaccines/BioDefense	$	557,211	$	689,266
BioTherapeutics		658,593		753,767
Corporate		4,695,661		6,780,625
Total	$	5,911,465	$	8,223,658